DJIA 17,279.74 13.75 0.08%
NASDAQ 4,579.79 -13.64 -0.30%
S&P 500 2,010.40 -0.96 -0.05%
market minute promo

16.02 -0.37 (-2.26%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

NBIX $16.02 -2.26%
Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $16.51
Previous Close $16.39
Daily Range $15.83 - $16.73
52-Week Range $8.57 - $20.29
Market Cap $1.2B
P/E Ratio -24.10
Dividend (Yield) $0.00 (0.0%)
Volume 785,495
Average Daily Volume 482,818
Current FY EPS -$0.80

Sector

Healthcare

Industry

Drugs

Neurocrine Biosciences, Inc. (NBIX) Description

Discovers, develops and intend to commercialize drugs for the treatment of neurological and endocrine-related diseases and disorders. Product candidates will target insomnia, anxiety, depression, cancer, diabetes, and multiple sclerosis. Website: http://www.neurocrine.com/

News & Commentary

Will These 3 Drugs Keep AbbVie's Future Bright After Humira?

While generic drugmakers will have a whale of a challenge creating a biosimilar of AbbVie's star drug Humira, this big pharma's thinking ahead with three up-and-coming drugs developing in its pipeline.

Neurocrine Biosciences' (NBIX) CEO Kevin Gorman Presents at Morgan Stanley Healthcare Conference (Tr

Neurocrine Biosciences' (NBIX) CEO Kevin Gorman Presents at Morgan Stanley Healthcare Conference (Transcript)

The Best Hedge Fund You've Never Heard Of and Its Top 5 Stock Picks

New Analyst Biotech Stocks to Buy With Gigantic Implied Upside

Neurocrine Biosciences Moving Ahead With '854

Neurocrine Biosciences' (NBIX) CEO Kevin Gorman on Q2 2014 Results - Earnings Call Transcript

2 Biotechs Race To Treat Movement Disorders

Neurocrine In "Hurry Up And Wait" Mode

Neurocrine Biosciences' (NBIX) CEO Kevin Gorman Presents at Bank of America Merrill Lynch 2014 Healt

Neurocrine Biosciences' (NBIX) CEO Kevin Gorman Presents at Bank of America Merrill Lynch 2014 Health Care Conference (Transcript)

Neurocrine Biosciences' (NBIX) CEO Kevin Gorman on Deutsche Bank 39th Annual Health Care Conference

Neurocrine Biosciences' (NBIX) CEO Kevin Gorman on Deutsche Bank 39th Annual Health Care Conference (Transcript)

Bullish Two Hundred Day Moving Average Cross - NBIX

See More NBIX News...

NBIX's Top Competitors

NBIX $16.02 (-2.26%)
Current stock: NBIX
AMGN $144.01 (1.40%)
Current stock: AMGN
GILD $105.96 (0.03%)
Current stock: GILD
BIIB $329.24 (-0.23%)
Current stock: BIIB